Sample Name
Sample Code
Sample Name
Sample Code
Sample Name
Sample Code
4
Direxion Daily S&P 500 Bear 3X Shares ETF
SPXS
5
T-Rex 2x Inverse Tesla Daily Target ETF
TSLZ
US Stock MarketDetailed Quotes
REPL Replimune
- 9.120
- +0.070+0.77%
Trading Apr 28 15:46 ET
702.37MMarket Cap-2.97P/E (TTM)
9.280High9.020Low321.16KVolume9.110Open9.050Pre Close2.93MTurnover0.61%Turnover RatioLossP/E (Static)77.01MShares17.00052wk High1.46P/B483.39MFloat Cap4.92052wk Low--Dividend TTM53.00MShs Float54.850Historical High--Div YieldTTM2.87%Amplitude4.920Historical Low9.130Avg Price1Lot Size
About Replimune Company
Replimune Group, Inc. is a clinical-stage biotechnology company. It engages in the business of developing oncolytic immunotherapies for the treatment of cancer. The company was founded by Philip Astley-Sparke, Colin A. Love, and Robert Coffin in March 2015 and is headquartered in Woburn, MA.
Company Profile
SymbolREPL
Company NameReplimune
Listing DateJul 20, 2018
Issue Price15.00
Founded2017
CEODr. Sushil Patel, PhD
MarketNASDAQ
Employees331
Fiscal Year Ends03-31
Address500 Unicorn Park Drive,Suite 303,3rd Floor
CityWoburn
ProvinceMassachusetts
CountryUnited States of America
Zip Code01801
Phone1-781-222-9600
Websitehttp://www.replimune.com
Company Executives
- Name
- Position
- Salary
- Dr. Sushil Patel, PhD
- Director and Chief Executive Officer
- --
- Paul Bullock
- Chief Manufacturing Officer
- --
- Andrew Schwendenman
- Chief Accounting Officer
- --
- Emily Hill
- Chief Financial Officer
- 3.38M
- Christopher Sarchi
- Chief Commercial Officer
- --
- Dr. Konstantinos Xynos, M.D.
- Chief Medical Officer
- 2.45M
- Philip Astley-Sparke
- Executive Chairman of the Board
- 6.02M
- Veleka Peeples-Dyer
- Independent Director
- 667.97K
- Christy J. Oliger
- Independent Director
- 352.60K
- Paolo Pucci
- Independent Director
- 360.10K
- Joseph P. Slattery, C.P.A.
- Independent Director
- 362.60K
- Dieter Weinand
- Lead Independent Director
- 516.81K
- Dr. Kapil Dhingra, M.B.B.S.
- Independent Director
- 357.60K
- Madhavan Balachandran
- Independent Director
- --
- Michael Goller
- Independent Director
- --
Market Insights
Discussing
2025 Buffett shareholders' meeting: What's the new buzz in value investing?
🎙️Discussion 1. In the face of market changes, do you prefer to stick with growth stocks or switch to value stocks? 2. Based on the current
Moomoo News Global
Apr 9 20:29
Learning From Buffett: Investing Wisely Amid Market Volatility Triggered by Trump's Tariffs
Fed Rate Cut Beneficiaries Fed Rate Cut Beneficiaries
Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data. Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data.
Unlock Now
U.S Tech Companies U.S Tech Companies
U.S leading technology companies with strong market presence, influential in their industries, and notable for robust innovation and profitability. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S Tech Companies, ranked from highest to lowest based on real-time market data. U.S leading technology companies with strong market presence, influential in their industries, and notable for robust innovation and profitability. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S Tech Companies, ranked from highest to lowest based on real-time market data.
Unlock Now
